Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: An observational study

Clinical Reviews in Allergy and Immunology

Volumn 38, Issue 2-3, 2010, Pages 90-96

  Filippini, Matteo ^a   Bazzani, Chiara ^a   Favalli, Ennio Giulio ^b   Marchesoni, Antonio ^b   Atzeni, Fabiola ^c   Sarzi Puttini, Piercarlo ^c   Pallavicini, Francesca Bobbio ^d   Caporali, Roberto ^d   Gorla, Roberto ^a  

^a Rheumatology and Clinical Immunology Unit   (Italy)

^b UOC Day Hospital of Rheumatology   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Adverse events; Elderly patients; Elderly onset rheumatoid arthritis; LORHEN database; Younger onset rheumatoid arthritis

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL STATUS; HUMAN; INFECTION; LOW DRUG DOSE; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; NEOPLASM; OBSERVATIONAL STUDY; RHEUMATOID ARTHRITIS; SEROLOGY;

ADOLESCENT; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; MIDDLE AGED; RECOVERY OF FUNCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 77953326679     PISSN: 10800549     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12016-009-8142-1     Document Type: Article

References (19)

1. Cimmino MA, Parisi M, Moggiana G, Mela GS, Accardo S (1998) Prevalence of rheumatoid arthritis in Italy: the Chiavari study. Ann Rheum Dis 57:315-318
2. van Schaardenburg D, Lagaay AM, Breedveld FC, Hijmans W, Vandenbroucke JP (1993) Rheumatoid arthritis in a population of persons aged 85 years and over. Br J Rheumatol 32:104-109
3. Deal CL, Meenan RF, Goldenberg DL, Anderson JJ, Sack B, Pastan RS, Cohen AS (1985) The clinical features of elderly-onset rheumatoid arthritis. A comparison with younger-onset disease of similar duration. Arthritis Rheum 28:987-994
4. van Schaardenburg D, Breedveld FC (1994) Elderly-onset rheumatoid arthritis. Semin Arthritis Rheum 23:367-378
5. Olivieri I, Palazzi C, Peruz G, Padula A (2005) Management issues with elderly-onset rheumatoid arthritis. An update. Drugs Aging 22:809-822
6. Fleischmann RM, Baumgartner SW, Tindall EA, Weaver AL, Moreland LW, Schiff MH et al (2003) Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. J Rheumatol 30:691-696
7. Dahl SL, Samuelson CO, Williams HJ, Ward JR, Karg M (1990) Second-line antirheumatic drugs in the elderly with rheumatoid arthritis: a post hoc analysis of three controlled trials. Pharmaco-therapy 10:79-84
8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1998) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324
9. Valesini G, Montecucco C, Cutolo M (2006) Recommendations for the use of biologic (TNF-alpha blocking) agents in the treatment of rheumatoid arthritis in Italy. Clin Exp Rheumatol 24:413-423
10. On behalf of the EULAR standing committee for international clinical studies including therapeutic trials, Van Riel PLCM, van Gestel AM, Scott DL (2000) The EULAR handbook of clinical assessment in rheumatoid arthritis. Van Zuiden Communications, Alpen an den Rijn
11. Ranza R, Marchesoni A, Calori G, Bianchi G, Braga M, Canazza S et al (1993) The Italian version of the functional disability index of the health assessment Questionnaire. A reliable instrument for multicenter studies on rheumatoid arthritis. Clin Exp Rheumatol 11:123-128
12. Bathon JM, Fleischmann RM, Van der Heijde D, Tesser JR, Peloso PM, Chon Y, White B (2006) Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol 33:234-243 (Pubitemid 43209297)
13. Aletaha D, Ward MM (2006) Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials. Ann Rheum Dis 65:227-233
14. Kauppi M, Hartikainen S, Kautiainen H, Laiho K, Sulkava R (2005) Capability for daily activities in old people with rheumatoid arthritis: a population based study. Ann Rheum Dis 64:56-58
15. Genevay S, Finckh A, Ciurea A, Chamot AM, Kyburz D, Gabay C (2007) Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 57: 679-685
16. Gorla R, Cavagnola L. 2004. Approccio multidisciplinare nel trattamento dell'AR. In La riabilitazione nelle malattie reumatiche. Percorsi clinici, progetto e programma riabilitativo. Edited by Mattioli 1885. Fidenza pp 316-324.
17. Yung RL (2000) Changes in immune function with age. Rheum Dis Clin North Am 26:455-473
18. Askling J, Bongartz T (2008) Malignancy and biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol 20:334-349
19. Geborek P, Bladstrom A, Turesson C, Gulfe A, Peterson IF, Saxne T, Olsson H, Jacobsson LTH (2005) Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64:699-703